21770 Federal Register / Vol. 65, No. 79 / Monday, April 24, 2000 / Notices

Assessment, Public Health Activities,

and the Studies Workgroups; and to

address other issues and topics, as

necessary.

Matters To Be Discussed: Agenda

items include discussion on the

summary of Hanford Health Information

Network (HHIN) project, update on

Individual Dose Assessment (IDA)

project, and reports from agency and

work groups. Agenda items are subject

to change as priorities dictate.

Contact Persons for More Information:

Leslie C. Campbell, Executive Secretary

HHES, Division of Health Assessment

and Consultation, ATSDR, 1600 Clifton

Road, NE M/S E–56, Atlanta, Georgia

30333, telephone 1–888/42–

ATSDR(28737), fax 404/639–0654.

The Director, Management Analysis

and Services office has been delegated

the authority to sign Federal Register

notices pertaining to announcements of

meetings and other committee

management activities, for both the

Centers for Disease Control and

Prevention and the Agency for Toxic

Substances and Disease Registry.

Dated: April 18, 2000.

John Burckhardt,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention.

[FR Doc. 00–10081 Filed 4–23–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

National Center for Health Statistics

(NCHS), Data Policy and Standards

Staff, Announces the Following

Meeting

Name: ICD–9–CM Coordination and

Maintenance Committee meeting.

Time and Date: 9 a.m.–5 p.m., May

11, 2000.

Place: The Health Care Financing

Administration, Multipurpose room,

7500 Security Boulevard, Baltimore,

Maryland.

Status: Open to the public.

Purpose: The ICD–9–CM Coordination

and Maintenance (C&M) Committee will

hold its first meeting of the calendar

year 2000 cycle on Thursday, May 11,

2000. The C&M meeting is a public

forum for the presentation of proposed

modifications to the International

Classification of Diseases, NinthRevision, Clinical Modification.

Matters to be Discussed: Agenda items

include:

Head injuries

Mammografic microcalcification

Myofascial pain syndrome

Stress Fracture

Periventricular leukomalacia

Posttraumatic wound infection versus

complicated open wound

Premature menopause

Update on the ICD–10–PCS coding

system

Thoracic aortic aneurysm repair

Lysis of adhesions

Penile plethysmography with nerve

stimulation

Percutaneous endoscopic

gastrojejunostomy (PEJ)

Spinal fusion for pseudoarthosis

Addenda

Contact Person for Additional

Information: Amy Blum, Medical

Classification Specialist, Data Policy

and Standards Staff, NCHS, 6526

Belcrest Road, Room 1100, Hyattsville,

Maryland 20782, telephone 301/458–

4106 (diagnosis), Amy Gruber, Health

Insurance Specialist, Division of Acute

Care, HCFA, 7500 Security Blvd., Room

C4–07–07, Baltimore, Maryland, 21244

telephone 410–786–1542 (procedures).

Notice: In the interest of security, the

H.C.F.A. has instituted stringent

procedures for entrance into the

building by non-government employees.

Persons without a government I.D. will

need to show a photo I.D. and sign-in at

the security desk upon entering the

building.

Notice: This is a public meeting.

However, because of fire code

requirements, should the number of

attendants meet the capacity of the room

the meeting will be closed.

The Director, Management Analysis

and Services Office, has been delegated

the authority to sign Federal Register

notices pertaining to announcements of

meetings and other committee

management activities, for both CDC

and the Agency for Toxic Substances

and Disease Registry.

Dated: April 18, 2000.

John Burckhardt,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 00–10082 Filed 4–23–00; 8:45 am]

BILLING CODE 4160–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Invention;

Availability for Licensing: ‘‘Prostate

Cancer Therapeutic and in vitro

Diagnostic Method to Screen for the

Presence of Metastatic Prostate

Cancer—A Monoclonal Antibody

Specific to Prostate Cells’’

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The invention listed below is

owned by an agency of the U.S.

Government and is available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of federally

funded research and development.

ADDRESSES: Licensing information may

be obtained by contacting J. R. Dixon,

Ph.D., at the Office of Technology

Transfer, National Institutes of Health,

6011 Executive Boulevard, Suite 325,

Rockville, Maryland 20852–3804

(telephone 301/496–7056 ext 206; fax

301/402–0220; E-Mail:

jd212g@NIH.GOV). A signed

Confidential Disclosure Agreement is

required to receive a copy of any patent

application.

SUPPLEMENTARY INFORMATION:

Invention Title: ‘‘Monoclonal

Antibodies to Prostate Cells’’.

Inventor: Dr. Ira H. Pastan (NCI).

USP SN: 5,489,525 [= DHHS Ref. No.

E–201–92/0]—Issued on February 6,

1996.

Abstract

Prostate Cancer is a disease affecting

approximately 1 million men in the

U.S.A., with an annual incidence of

around 179,000 and approximately

30,000 deaths per year. It is estimated

that one-third of men over 50 will

develop prostate cancer at some time in

their lives. Control of primary tumor by

surgical resection and/or radiation has

proven effective in a number of cases,

however, metastatic spread, primarily to

the bone, especially at late hormone

independent stages of the disease, has

been more difficult to control and

monitor. With the aging of the U.S.

population, it has been estimated that

the number of prostate cancer cases will

increase dramatically.

Technology

The technology disclosed in the

5,489,525 patent relates to a monoclonal

antibody which is capable of binding to

a cell surface differentiation antigen